Clinical trials: Metabolism and Excretion
Healthy Volunteers
A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants
This study is to determine the absolute bioavailability of oral acalabrutinib and intravenous (IV) PK of [14C]ACP-196.
- Trial name
- NCT04898101
- Testing
- Acalabrutinib, Microtracer [14C]ACP-196
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Acerta Pharma BV
Lipid Disorder, Triglycerides High
Vascepa to Accelerate Lipoprotein Uptake and Elimination
This study is a Phase 1 pilot/feasibility mechanistic experiment to help clarify the mechanism of action of an EPA-rich fish oil preparation, icosapent ethyl, on lipid changes in statin-treated patients with residual…
- Conditions
- Lipid Disorder, Triglycerides High, Dyslipidemias
- Trial name
- VALUE (NCT03885661)
- Testing
- Icosapent Ethyl 1000 MG [Vascepa]
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
- Trial name
- NCT07868926
- Testing
- 14C-VX-407
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy Volunteer
A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)
This Phase I study is designed to determine the excretion balance of radiocarbon, as the sum of carbon-14 (14C)-labeled TRO19622 and its 14C-metabolites, and to investigate the pharmacokinetics and metabolic profile of TRO19622…
- Trial name
- NCT02835976
- Testing
- Olesoxime
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Carcinoma, Renal Cell
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
- Trial name
- NCT00478725
- Testing
- GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Hyperkalemia, Diminished Renal Excretion
Evidence for Potassium Restriction in Hemodialysis
EvoKe-HD is a pilot randomized controlled trial to assess the feasibility and potential for efficacy of a novel dietary approach to hyperkalemia.
- Trial name
- EvoKe-HD (NCT06120608)
- Testing
- Novel dietary approach focused on restricting the intake of highly bioavailable potassium, Traditional approach
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Rest Cramps
Exploring the Role of Magnesium in Rest Cramps
This study sets out to show whether infusions of magnesium can lessen the frequency of rest cramps and to determine whether rest cramp sufferers have a deficiency in magnesium.
- Trial name
- NCT00423540
- Testing
- Intravenous Infusion of Magnesium Sulfate
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Healthy
Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects
This is a single centre, open-label, non-randomised study to assess the mass balance recovery, absorption, metabolism, and excretion of a single oral dose of [14C]-NT-814 in healthy male subjects.
- Trial name
- NCT04654897
- Testing
- [14C]-NT-814
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib
This is a single-center, open label and single-dose clinical trail, to explore the body mass balance and identify the major metabolites in Chinese adult male healthy volunteers after a single oral dose of [14C]Sulfatinib, to…
- Trial name
- NCT03627520
- Testing
- [14C]Sulfatinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hutchison Medipharma Limited
Type 2 Diabetes Mellitus
Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin
The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.
- Trial name
- NCT02791035
- Testing
- Oral administration of Ipragliflozin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Healthy Adult Male Volunteers
ADME Study of [14C]- Larotinib in Healthy Male Subjects
Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]-Larotinib（Z650）in healthy male subjects.
- Trial name
- NCT05059743
- Testing
- [14C]-Larotinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Type 2 Diabetes
SGLT2 Inhibition: Uric Acid Excretion Study
The current study investigates the effects of SGLT2 inhibitor empagliflozin on uric acid excretion.
- Trial name
- UREX (NCT05210517)
- Testing
- Empagliflozin 25 MG, Benzbromaron, Empagliflozin 25 MG + benzbromarone 100 mg
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Amsterdam UMC, location VUmc
Cutaneous T Cell Lymphoma, Mycosis Fungoides
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Resminostat is a potent, orally available inhibitor of Class I, IIb and IV histone deacetylases (HDACs), including a pronounced activity against HDAC6.
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT04955340
- Testing
- [14C]-resminostat
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Healthy
A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
The purpose of this study is to learn what happens to enlicitide chloride labeled with [¹⁴C] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.
- Trial name
- NCT06658626
- Testing
- [¹⁴C]Enlicitide chloride
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteer
Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961
This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to evaluate the absolute oral bioavailability of…
- Trial name
- NCT04495140
- Testing
- [14C]PF-06882961, 50 mg, PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
- Where
- 2 sites in Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of [14C]-NX-5948.
- Trial name
- NCT06691828
- Testing
- NX-5948
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Nurix Therapeutics, Inc.
Healthy Volunteers
A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants
The purpose of this study is to determine: Period 1 (ABA): ABA of mobocertinib following single microdose intravenous administration of 50 microgram (mcg) (approximately 2 microcurie [mcCi]) [14 C]-]-mobocertinib and single oral…
- Trial name
- NCT03811834
- Testing
- Mobocertinib
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy
Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects.
This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK31858 in healthy male subjects.
- Trial name
- NCT06569784
- Testing
- [14C]HSK31858
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Xizang Haisco Pharmaceutical Co., Ltd
Healthy
[14C] Mass Balance Clinical Trial of Azvudine in Healthy Male Subjects
Azvudine(FNC)，a nucleoside reverse transcriptase inhibitor, make itself a better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's compliance.
- Trial name
- NCT07002281
- Testing
- [14C]Azvudine suspension
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Henan Genuine Biotech Co., Ltd.
Healthy Males
A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir
The goal of this clinical trial is to assess how the body processes, breaks down and removes a new test medicine (vapendavir) from the body in healthy male participants.The main question it aims to answer is how the body handles…
- Trial name
- NCT06834295
- Testing
- Vapendavir
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Altesa Biosciences, Inc.